



SPECIFIC DIAGNOSTICS Acquisition

April 12, 2022

PIONEERING DIAGNOSTICS

DISCLAIMER

- This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
- The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
- This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.

SPECIFIC DIAGNOSTICS - COMPANY HISTORY



- Based in San Jose, California
- 82 employees

2011 - Company Formed

2011 - First Smart Blood Culture NIH Grant
2015 - First NIH Rapid AST Grant Awarded

2019 - Private Equity Funding, Joined by bioMérieux


**2020 - CE-IVD Registration for Specific Diagnostics
Reveal Rapid AST System**

2021 - Co-Distribution in Europe with bioMérieux

2022 - FDA Clinical Studies Underway

FAST DIAGNOSTICS HAVE A KEY ROLE TO PLAY IN ANTIMICROBIAL STEWARDSHIP (AMS) & SEPSIS


Antimicrobial Resistance (AMR): the Silent Pandemic



Stewardship & Infection Prevention
are key measures to address AMR fight



Sepsis: one of the most significant health complications that can result from any infection



**Every hour of delay in giving
appropriate antibiotics reduces the
chance to survive**

SPECIFIC REVEAL RAPID AST PROVIDES ACTIONABLE RESULTS FOR GRAM-NEGATIVE BACTERIA IN AN AVERAGE OF 5 HOURS

SPECIFIC REVEAL™ RAPID-AST




 **FAST**
FROM POSITIVE BLOOD CULTURE
RESULTS IN AN AVERAGE 5H*

 **ACTIONABLE**
WIDE ANTIMICROBIAL COVERAGE
FOR BLOODSTREAM GRAM NEGATIVE INFECTION

 **EASE OF USE**
QUICK SAMPLE PREP <3mn
MODULAR TO ADJUST THROUGHPUT AS NEEDED

AST TECHNOLOGY BASED ON SMALL MOLECULE SENSORS



SPECIFIC'S NOVEL AND PATENTED SMALL MOLECULE SENSOR ARRAY


Each sensor generates a colorimetric (color change) reaction to the metabolic volatiles (volatile organic compounds, VOCs) released by microorganisms during growth



Time 0

4 Hours

Sensor Response



Determination of MIC's

KEY TERMS

SPECIFIC REVEAL™ RAPID-AST



- Acquisition price: **425M\$**, paid in cash and in shares
- Intend to **offset the 1% share dilution** through a share buy back program post closing
- Revenue projection: **> 60M\$ on year 5**
- Dilutive on CEBIT for ~10 M€* in 2022 and ~15 M€* in 2023 due to product launch stage and R&D expenses, **expected to become accretive from 2025***
- **Closing expected in Q2 2022**

THE ADDITION OF SPECIFIC REVEAL TO BIOMERIEUX SEPSIS SOLUTION ALLOWS TO ADDRESS THE BLOOD CULTURE (BC) GRAM NEGATIVE MAJOR UNMET NEED WITH A UNIQUE RAPID WORKFLOW

CURRENTLY observed on the market

Average time-to-AST for Blood Cultures in real life
Non-optimized workflow

60h*

bioMérieux ROUTINE
 integrated solution for BC GRAM Positive

BC → Gram & Subculture → ID / AST

Collection & transport (VIRTUO) → PREVI COLOR GRAM → Subculture on PPM → VITEK MS PRIME → VITEK 2

42h*

bioMérieux RAPID
 fastest integrated solution on the market for BC GRAM Negative

BC → Gram → Fast ID / AST

Collection & transport (VIRTUO) → PREVI COLOR GRAM → BIOFIRE BCID2 → SPECIFIC REVEAL

Same day

THIS ACQUISITION STRENGTHENS BIOMÉRIEUX LEADERSHIP IN MICROBIOLOGY OFFERING BEST IN CLASS SOLUTION & ADDRESSING KEY CLINICAL UNMET NEEDS



BACTALERT®
VIRTUO




BIOFIRE®
BCID2



VITEK®
MS PRIME



SPECIFIC
REVEAL™



VITEK® 2



CONNECTED & INTEGRATED WITH MYLA® MIDDLEWARE



LAB CONSULTANCY



MYLA®



PIONEERING DIAGNOSTICS